Compare Regeneron Pharmaceuticals Inc (REGN) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Transocean Ltd — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Transocean Ltd trades at $5.75 (market cap $6.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 13× Transocean Ltd's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| REGN | RIG | |
|---|---|---|
Market Cap | $83.43B | $6.43B |
Sector | Health | Technology |
52-Week High | $852.03 | $7.58 |
52-Week Low | $555.51 | $3.08 |
Enterprise Value | $78.14B | $11.04B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Transocean (RIG) trades at $5.76, down 1.54% today, with a bearish technical signal despite recent earnings beat. The company shows improving operational cash flow ($995M in 2026) and secured a $300M contract with ONGC, but faces challenges with negative net income margins (-40.24%) and high debt levels. Analyst sentiment is mixed with 39% buy ratings amid ongoing profitability concerns.
RIG presents a high-risk opportunity with improving contract backlog and cash flow generation potential offset by substantial debt burden and inconsistent earnings performance. Investors should weigh the company's exposure to volatile oil prices against its position in the tightening deepwater drilling market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
